pyrazines has been researched along with Epithelial Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartelink-Clements, C; Basmeleh, A; Batlle, E; Boj, SF; Cabellos, L; Cañellas-Socias, A; Chicote, I; Clevers, H; Cortina, C; de Kruif, J; Eppink, B; Fatrai, S; Glodzik, D; Hernando-Momblona, X; Herpers, B; James, MI; Lammerts van Bueren, JJ; Logtenberg, T; Mateos, JG; Maussang, D; Nuciforo, P; Palmer, HG; Price, LS; Ramírez, L; Roovers, RC; Salazar, R; Salinaro, L; Sancho, E; Santos, C; Serna, G; Stephan-Otto Attolini, C; Stratton, MR; Tabernero, J; Throsby, M; van de Wetering, M; Villanueva, A; Vries, RGJ; Yan, K; Zondag-van der Zande, V | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
| Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG | 1 |
| Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E | 1 |
1 trial(s) available for pyrazines and Epithelial Neoplasms
| Article | Year |
|---|---|
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
3 other study(ies) available for pyrazines and Epithelial Neoplasms
| Article | Year |
|---|---|
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Topics: Antibodies, Bispecific; ErbB Receptors; Humans; Imidazoles; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Organoids; Pyrazines; Receptors, G-Protein-Coupled | 2022 |
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53 | 2009 |
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53 | 2005 |